Marker Therapeutics Inc (MRKR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $13.82M
Last updated: Nov 17, 2026 at 4:31 PM ET
Marker Therapeutics Inc (MRKR) Statistics
Marker Therapeutics (MRKR) has a market cap of $13.82M and an enterprise value of $4.78M. It kept -775.14% of revenue as net income over the last 12 months. Its share count is up 15.26% from a year earlier.
Total Valuation
Enterprise value is 65.43% below the market cap, as cash exceeds debt.
| Market Cap | $13.82M |
|---|---|
| Enterprise Value | $4.78M |
| Latest price (Nov 17, 2026) | $0.84 |
Key Dates
The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 16, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 14.6x and 1.5x. Its year-end P/S ranged from 2.2x to 617.8x from 2019 to 2025.
| P/S Ratio | 14.6x |
|---|---|
| Forward P/S | 3.3x |
| P/B Ratio | 1.5x |
Price Statistics
The stock is down 9.36% over 52 weeks and trades 19.23% below its 50-day average.
| Beta (1Y) | 1.29 |
|---|---|
| 52-Week Change | -9.36% |
| 1-Month Change | -30.28% |
| 3-Month Change | -35.15% |
| 6-Month Change | -39.81% |
| 5-Year Change | -93.33% |
| 10-Year Change | -98.04% |
| Total Return (1Y) | -9.36% |
| Total Return (3Y CAGR) | -33.53% |
| Total Return (5Y CAGR) | -41.89% |
| Max Drawdown (1Y) | -62.16% |
| Max Drawdown (3Y) | -86.10% |
| Sharpe Ratio (1Y) | -0.23 |
| Correlation with SPY (1Y) | 0.22 |
| 50-Day Average | $1.04 |
| 200-Day Average | $1.31 |
| 52-Week Range | $0.82 to $2.46 |
| RSI (14 Days) | 39.2 |
| Average Volume (20 Days) | 123.51K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.26x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.26x |
|---|---|
| Quick Ratio | 6.26x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -81.44% over the last 12 months, against a 5-year average of -87.35%.
| Return on Equity (ROE) | -81.44% |
|---|---|
| Return on Assets (ROA) | -68.43% |
| Return on Capital Employed (ROCE) | -86.45% |
| ROE (5Y Average) | -87.35% |
| ROA (5Y Average) | -61.80% |
| ROIC (5Y Average) | -75.95% |
| Asset Turnover | 0.06x |
| Receivables Turnover | 0.55x |
Scores
MRKR has an Altman Z-Score of -48.64, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -48.64 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $1.10M over the last 12 months is down 51.00% from the 12 months before.
| Revenue | $1.10M |
|---|---|
| Revenue Growth (YoY) | -51.00% |
| Gross Profit | $1.10M |
| Operating Income | -$11.81M |
| Pretax Income | -$12.91M |
| Net Income | -$8.55M |
| EBITDA | -$9.08M |
| EBIT | -$9.08M |
| Reported EPS (TTM) | -$0.39 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 84.00% of the $12.50M in total assets.
| Cash and Equivalents | $9.04M |
|---|---|
| Total Debt | $0 |
| Net Cash | $9.04M |
| Net Cash Per Share | $0.47 |
| Working Capital | $10.50M |
| Shareholder Equity | $10.50M |
| Book Value Per Share | $0.54 |
| Total Assets | $12.50M |
| Total Liabilities | $2.00M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$9.52M |
|---|---|
| FCF Per Share | -$0.57 |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -1069.94%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -1069.94% |
| Pretax Margin | -1169.59% |
| Net Margin | -775.14% |
| EBITDA Margin | -822.87% |
| EBIT Margin | -822.87% |
Growth
Revenue grew 0.31% a year over 3 years.
| Revenue Growth (3Y CAGR) | +0.31% |
|---|---|
| Revenue Growth (5Y CAGR) | +50.02% |
| Book Value Per Share Growth (2Y CAGR) | -16.64% |
| Tangible Book Per Share Growth (2Y CAGR) | -16.64% |
Stock Splits
The last split was a 1-for-10 reverse split on Jan 27, 2023.
| Last Split Date | Jan 27, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 4 similar companies, MRKR has the 2nd highest P/S.
P/S RatioPeer median 5.2x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -83.16%
| P/S Ratio | 14.6x vs 5.2x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -51.00% vs -83.16% median |
Analyst Forecast
Consensus estimates put revenue growth at 138.57% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +138.57% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MRKR
What is MRKR's market cap?
Marker Therapeutics has a market cap of $13.82M. Its enterprise value, which adds debt and subtracts cash, is $4.78M.
How many shares of MRKR are outstanding?
Marker Therapeutics has 19.31M shares outstanding. The count is up 15.26% from a year earlier.
Does MRKR pay a dividend?
No. Marker Therapeutics does not pay a dividend.
How much debt does MRKR have?
Marker Therapeutics has $0 of total debt and $9.04M of cash and equivalents, a net cash position of $9.04M.
MRKR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors